分子亚型和基因组分析在KRAS野生型胰腺癌中扩大精准医学
Dan Su1,2, Yuli Ruan1,2,3, Yingfei Shi4
1Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Cancer science
|January 20, 2025
概括
KRAS野生型胰腺癌存在可操作的突变和融合,提供了新的精确治疗选择. 识别这些变化是改善这种患者群体治疗结果的关键.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 精准医学是一门精准的医学.
背景情况:
- 胰腺管腺癌 (PDAC) 的预后不佳,大多数病例是由KRAS突变驱动的.
- 一个PDAC (8-10%) 的子集是KRAS野生型 (KRAS-WT),可能存在可向的基因组改变.
- 识别这些KRAS-WT特异性变化对于开发新型治疗策略至关重要.
研究的目的:
- 在KRAS-WT PDAC中识别可操作的突变和基因融合.
- 探索基于已识别的分子形状的潜在治疗策略.
- 为了将研究结果与癌症基因组图谱的胰腺腺癌 (TCGA-PAAD) 数据进行比较.
主要方法:
- 对34名KRAS-WT PDAC患者的回顾性分析.
- 下一代测序 (NGS) 和RNA测序用于基因组分析.
- 生物信息解卷用于评估免疫透.
主要成果:
- 在多个途径中发现了可向的改变,包括ATM (18%),PIK3CA (15%) 和ROS1 (15%) 突变.
- 有效的基因融合 (例如,CCDC6-RET,ETV6-NTRK3) 在10.3%的患者中存在.
- 同源重组缺陷 (HRD) 突变预测了敏感性 (p=0.047);表观遗传基因突变与免疫细胞透相关.
结论:
- 克拉斯-WT PDAC含有可操作的突变和融合,为向和基于免疫的治疗提供了机会.
- 特定突变表明对基化疗和免疫检查点抑制剂 (ICI) 的敏感性.
- 激酶融合表明对larotinib等向抑制剂的潜在反应;需要进一步的临床验证.
相关概念视频
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:38The Ras Gene
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Ras is a superfamily...
01:24Small GTPases - Ras and Rho
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity: